Overview

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Veliparib